Global Threat Escalates: Antibiotic Resistance Surging, WHO Report Warns
Table of Contents
Antimicrobial resistance (AMR) is rapidly compromising the effectiveness of life-saving treatments worldwide, with a particularly alarming rise in resistance among common, dangerous bacteria, according to a new report released October 13 by the World Health Organization (WHO). The findings,stemming from the organization’s Global Antimicrobial Resistance and Use Surveillance System (GLASS),paint a dire picture of a growing global health crisis.
A Four-Fold Increase in Surveillance, But Dire Findings
As its inception in 2016, the number of countries participating in GLASS has increased four-fold, allowing for more comprehensive data collection. However, the report reveals a concerning trend: resistance to several key antibiotics is increasing at an alarming rate. Specifically,resistance to antibiotics used to treat common infections like pneumonia,bloodstream infections,and urinary tract infections is on the rise. The report highlights increasing resistance in pathogens, including Acinetobacter spp, E. coli, K. pneumoniae, and Salmonella spp. These antibiotics are essential for treating severe infections, and their diminishing effectiveness is already impacting treatment options. rising AMR is forcing a shift from oral to intravenous treatments and increasing reliance on second-choice and last-resort antibiotics.
A “Syndemic” of Inequality and Weak Health Systems
The WHO investigators found a strong link between socioeconomic factors and the burden of AMR. Their analysis revealed an inverse correlation between a country’s universal health coverage service index and income levels, and the prevalence of AMR in bloodstream infections.This pattern,they argue,points to a “syndemic” – a convergence of epidemics – where AMR disproportionately affects nations with weaker health systems and lower incomes.
“This pattern points to a syndemic, in which AMR disproportionately affects countries with weaker health systems and lower income levels,” the report states. Countries with limited surveillance capabilities often exhibit higher resistance levels, underscoring the need for strengthened laboratories and data systems in under-resourced regions.
Urgent Call to Action: Stewardship, Diagnostics, and Access
The report urges nations to prioritize three key measures to combat AMR. These include integrating surveillance into routine clinical practice, strengthening access to quality-assured diagnostics for bacterial and fungal infections, and investing in robust digital information systems. A critical component of this strategy is bolstering antibiotic stewardship programs.
Currently,only 52.7% of global antibiotic use falls within the “Access” category – antibiotics that should be widely available as first- or second-line treatments for common infections. This falls substantially short of the United Nations’ 2030 target of 70%. Conversely, “Watch” antibiotics, with higher resistance potential, comprised 45.3% of global use in 2022, exceeding 70% in nearly one-third of countries.
The Escalating Cycle of Resistance and Cost
As resistance to lower-cost antibiotics rises, healthcare providers are increasingly prescribing more expensive options like carbapenems. when resistance develops to these as well, treatment frequently enough falls back on the “Reserve” group of antibiotics – drugs reserved for multi-drug resistant infections. These last-resort options are frequently enough unaffordable and inconsistently available, and require diagnostic confirmation that is frequently unavailable in under-resourced settings.
The WHO classifies antibiotics using the aware framework, categorizing them as “Access,” “Watch,” and “Reserve” to guide appropriate use. The report emphasizes that the disproportionate reliance on broad-spectrum antibiotics is a major driver of AMR.
“These patterns indicate an urgent need to strengthen antibiotic stewardship and ensure equitable access to effective essential antibiotics at all levels of care,” the GLASS investigators declare. Addressing this escalating crisis requires a concerted global effort to preserve treatment effectiveness and ensure equitable access to essential medicines for all.
Reference:
- WHO. Global Antibiotic Resistance Surveillance Report 2025. 2025,October 13. https://www.who.int/publications/i/item/9789240116337.
